Nature Biotechnology 2006 Brian Vastag - Abstracts
| Nature Biotechnology 2006 Brian Vastag | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| Alfimeprase to succeed Genentech's alteplase? | Business | Brian Vastag | |||
| HSP-90 inhibitors promise to complement cancer therapies. | Business | Brian Vastag | |||
| New clinical trials policy at FDA. | Business | Brian Vastag | |||
| Tuft's report backs FDA fast-track, but post-marketing concerns loom. | Business | Brian Vastag | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.